市場調査レポート

エボラウイルス病治療薬およびワクチン世界市場の将来性分析(パイプライン分析、薬剤、ワクチン、地域)

Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020

発行 Allied Market Research 商品コード 316325
出版日 ページ情報 英文 55 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
エボラウイルス病治療薬およびワクチン世界市場の将来性分析(パイプライン分析、薬剤、ワクチン、地域) Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020
出版日: 2014年09月14日 ページ情報: 英文 55 Pages
概要

エボラ出血熱(EHF)として知られるエボラウイルス病(EVD)は、エボラウイルスとその他3種の遺伝子的に密接な関連性を持つウィルス(関連ウィルス属)を病原とするもので、その初期症状には喉の痛みや頭痛、発熱、筋肉痛などが挙げられ、これが体内・体外の出血を引き起こす出血熱に至ります。この疾患は広く中央・西アフリカの熱帯雨林周辺に蔓延中であり、高い致死率、そして決め手となる治療法が存在しないことから、医薬品メーカーには追及すべき大きな商機をもたらすものです。

当レポートでは、エボラウイルス病関連の世界市場に注目し、今後の発展の可能性を開発パイプライン、治療薬・ワクチンなどの製品、地域の別に探るほか、その動向、推進・抑制要因、競合環境、主要参入企業などについての最新情報を集めています。

第1章 イントロダクション

  • レポートの主要利点
  • レポートの主要対象市場セグメント
  • レポートの推奨利用者層
  • 調査方法

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 重要所見
    • 市場成長に影響する主要ファクター
    • 主要資金源
    • 主要成功戦略
  • 主な市場参入企業の位置づけ
  • エボラウィルスの重要ファクト
    • エボラ病の感染
    • エボラ病の兆候と症状
    • エボラ病の診断法
    • 利用できるエボラ病治療薬やワクチン
  • 米国におけるエボラ病治療薬の改良
    • エボラ病患者の航空医療輸送に対する指導
  • 米国政府によるエボラ病治療薬研究への「ファストトラック」指定
  • ZMMP Drug:エボラウイルス病に対する希少ソリューション
  • 治療薬がもたらす倫理的ジレンマ
  • 米国食品医薬品局(FDA)資金によるエボラ病研究の加速を迫られたTekmira Pharma
  • 治験
  • 市場動態
    • 推進要因
    • 抑制要因
    • 機会

第4章 エボラ病ワクチンの予測シナリオ分析(単位:100万ドル)

  • 堅実成長シナリオ
  • 急成長シナリオ
  • マイナス成長シナリオ水平掘削

第5章 エボラ病治療ワクチン市場の世界的開発パイプラインおよび市場性分析 - 地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米・中東・アフリカ

第6章 企業プロフィール(企業概要、寸見、財務成績、戦略的動きおよび展開、SWOT分析など)

  • Tekmira Pharmaceuticals
  • BioCryst Pharmaceutical Inc.
  • Serepata Therapeutics
  • NewLink Genetics Corp.
  • Mapp Biopharmaceutical
目次
Product Code: PH 14503

Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests. Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD).

Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease.

KEY BENEFITS

This report offers the following benefits in particular:

  • To track commercial trends, major clinical trials and their status are pursued of closely
  • The report sheds light on the key events held in past years concerning the development of ebola viral disease therapeutics
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the ebola therapeutics and vaccines market
  • Porter's Five Forces analysis examines the competitive structure of the ebola therapeutics and vaccines market and would assist market strategists in their respective decision making process
  • In-depth coverage of the ebola therapeutics and vaccines market including drivers, restraints and opportunities would help professionals to better understand market behavior
  • Detailed study of the strategies of key leaders, partnerships and acquisitions in the ebola therapeutics and vaccines market would be informative for professionals in corporate sector

KEY MARKET SEGMENTS

Ebola therapeutics and vaccines market is segmented on the basis of geography.

  • LAMEA
  • North America
  • Europe
  • Asia-Pacific

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 Key Benefits
  • 1.2 Key Market Segment
  • 1.3 Key Audiences
  • 1.4 Research Methodology
    • 1.4.1 Primary Research
    • 1.4.2 Secondary Research
    • 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW

  • 3.1 Market Definition and Scope
  • 3.2 Key Findings
    • 3.2.1 Top factor impacting the market growth
    • 3.2.2 Top investment pockets
  • 3.3 Key market player positioning
  • 3.4 Ebola Virus Key Facts
    • 3.4.1 Transmission of Ebola
    • 3.4.2 Signs and symptoms of ebola
    • 3.4.3 Diagnosis of ebola
    • 3.4.4 Vaccine or treatment available for ebola
  • 3.5 Amend for anti-Ebola disease drugs in United States
  • 3.6 Guidance on Air Medical Transport for Patients with Ebola Virus Disease
  • 3.7 "Fast Track" designation to Anti-E bola drugs research from the U.S. government
  • 3.8 ZMMP Drug: An Orphan solution for E-bola viral disease
    • 3.8.1 ZMAPP is not ready for prime time
      • 3.8.1.1 Orphan Drugs for Orphan Diseases
  • 3.9 Ethical Dilemmas from therapeutics
  • 3.10 Tekmira Pharma received boost to ebola R&D through FDA fundings
  • 3.11 Clinical Trials
  • 3.12 Market Dynamics
    • 3.12.1 Drivers
      • 3.12.1.1 Prevalent cases and unpredictable nature of disease
      • 3.12.1.2 Increased rate of migration from developing countries
      • 3.12.1.3 Lack of relevant medication
    • 3.12.2 Restraints
      • 3.12.2.1 High initial investment for R&D
      • 3.12.2.2 Obstractive ethical considerations
    • 3.12.3 Opportunities
      • 3.12.3.1 Development of economic vaccines and drugs
      • 3.12.3.2 Gaining competitive edge in developing economies

CHAPTER 4 FORECASTE SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-2020, ($MILLION)

  • 4.1 Moderate growth scenario
  • 4.2 Rapid growth scenario
  • 4.3 Diminishing growth scenario

CHAPTER 5 GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF E-BOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY, 2013 - 2020

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 LAMEA

CHAPTER 6 COMPANY PROFILES

  • 6.1 Tekmira Pharmaceuticals
    • 6.1.1 Overview
    • 6.1.2 Company snapshot
    • 6.1.3 Financial performance
    • 6.1.4 Strategic moves and developments
    • 6.1.5 SWOT analysis
  • 6.2 BioCryst Pharmaceutical Inc.
    • 6.2.1 Overview
    • 6.2.2 Company snapshot of BioCryst Pharmaceutical Inc.
    • 6.2.3 Financial performance
    • 6.2.4 Strategic moves and developments
    • 6.2.5 SWOT analysis
  • 6.3 Serepata Therapeutics
    • 6.3.1 Overview
    • 6.3.2 Company snapshot
    • 6.3.3 Strategic moves and developments
    • 6.3.4 SWOT analysis
  • 6.4 NewLink Genetics Corp.
    • 6.4.1 Overview
    • 6.4.2 Company snapshot
    • 6.4.3 Financial performance
    • 6.4.4 Strategic moves and developments
    • 6.4.5 SWOT analysis
  • 6.5 Mapp Biopharmaceutical
    • 6.5.1 Overview
    • 6.5.2 Company snapshot
    • 6.5.3 Strategic moves and developments
    • 6.5.4 SWOT analysis of Mapp Biopharmaceutical

List of Tables

  • TABLE 1 CHRONOLOGY OF E-BOLA VIRUS INCIDENCE
  • TABLE 2 CLINICAL TRIAL NO I
  • TABLE 3 CLINICAL TRIAL NO II
  • TABLE 4 CLINICAL TRIAL NO III
  • TABLE 5 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 6 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 7 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 8 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 9 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 10 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 11 GLOBAL EVD POTENTIAL VACCINES MARKET BY GEOGRAPHY, 2015-2020, (THOUSAND UNITS)
  • TABLE 14 GLOBAL EVD VACCINES DEMAND BY GEOGRAPHY, 2015-2020, (UNITS IN THOUSAND)
  • TABLE 15 COMPANY SNAPSHOT OF TEKMIRA PHARMACEUTICALS
  • TABLE 16 COMPANY SNAPSHOT OF BIOCRYST PHARMACEUTICAL INC.
  • TABLE 17 COMPANY SNAPSHOT OF SEREPATA THERAPEUTICS
  • TABLE 18 COMPANY SNAPSHOT OF NEWLINK GENETICS CORP.
  • TABLE 19 COMPANY SNAPSHOT OF MAPP BIOPHARMACEUTICAL

List of Figures

  • FIG. 1 TOP IMPACTING FACTORS OF EBOLA VIRAL DISEASE DRUGS (2013-2020)
  • FIG. 2 TOP INVESTMENT POCKETS
  • FIG. 3 KEY MARKET PLAYER POSITIONING OF EBOLA THERAPEUTICS
  • FIG. 4 MILESTONE OF E-BOLA DISEASE PREVALENCE BY GEOGRAPHIES
  • FIG. 5 SURGED EBOLA INCIDENCES IN WEST AFRICA (2014)
  • FIG. 6 TEKMIRA'S NET REVENUE FROM RESEARCH COLLABORATIONS AND CONTRACTS (2013)
  • FIG. 7 SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS
  • FIG. 8 R&D EXPENSES OF BIOCRYST PHARMACEUTICAL INC. (2013)
  • FIG. 9 SWOT ANALYSIS OF BIOCRYST PHARMACEUTICAL INC.
  • FIG. 10 SWOT ANALYSIS OF SEREPATA THERAPEUTICS
  • FIG. 11 RESEARCH AND DEVELOPMENT EXPENSES BY PRODUCTS (2013)
  • FIG. 12 SWOT ANALYSIS OF NEWLINK GENETICS CORP.
  • FIG. 13 SWOT ANALYSIS OF MAPP BIOPHARMACEUTICAL
Back to Top